Physician profile
Mark W Johnson
NPI 1205838653
$9,283.21
in general payments reported to CMS, 2019-2025
35 companies · $1,130 in 2025
The $1,130 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,167 · 2020: $1,141 · 2021: $1,692 · 2022: $1,106 · 2023: $1,483 · 2024: $1,563 · 2025: $1,130.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,176.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,405.33 | 2019-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Grifols USA, LLC | $1,098.28 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $838.05 | 2019-2025 | Ofev, Spiriva Respimat, Stiolto Respimat |
| Astrazeneca Pharmaceuticals LP | $464.05 | 2019-2025 | Airsupra, Fasenra, Tezspire |
| Amgen INC. | $401.19 | 2023-2025 | Tezspire |
| Actelion Pharmaceuticals US, INC. | $318.73 | 2019-2024 | Opsumit |
| Janssen Pharmaceuticals, INC | $306.35 | 2019-2024 | Xarelto |
| Mylan Specialty L.P. | $220.50 | 2019-2024 | Yupelri |
| Genentech USA, INC. | $207.51 | 2019-2024 | Xolair |
| Takeda Pharmaceuticals U.S.A., INC. | $206.86 | 2020-2024 | Glassia |
| Pfizer INC. | $195.98 | 2023-2025 | |
| Baxter Healthcare | $173.17 | 2022-2024 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| United Therapeutics Corporation | $148.16 | 2019-2025 | Tyvaso, Tyvaso |
| Electromed, INC. | $144.67 | 2019-2025 | Smartvest |
| Penumbra, INC. | $135.64 | 2023 | Indigo System |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $118.03 | 2019-2024 | Dupixent |
| Abbvie INC. | $117.71 | 2021-2022 | |
| Genzyme Corporation | $105.40 | 2020-2024 | |
| Verona Pharma, INC. | $102.17 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $80.00 | 2019-2024 | Winrevair |
| Mallinckrodt Hospital Products INC. | $76.51 | 2020-2025 | Terlivaz |
| Nabriva Therapeutics, Plc | $70.86 | 2021-2022 | |
| Gilead Sciences, INC. | $49.68 | 2021 | |
| Inari Medical, INC. | $39.85 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Insmed, INC. | $33.31 | 2020-2025 | Arikayce |
| Sanofi-Aventis U.S. LLC | $33.19 | 2020-2021 | |
| Viatris Specialty LLC | $29.19 | 2025 | Yupelri |
| Philips North America LLC | $28.99 | 2021-2023 | |
| Allergan, INC. | $26.56 | 2019-2020 | |
| Inogen, INC. | $20.90 | 2022 | |
| Shire North American Group INC | $19.55 | 2019 | |
| Advanced Respiratory, INC | $17.80 | 2021 | |
| Movair INC | $17.25 | 2025 | Luisa |
| Teva Pharmaceuticals USA, INC. | $17.03 | 2021 | |
| Chiesi USA, INC. | $14.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.